Interprofessional Care of Patients with HR+/HER2− Metastatic Breast Cancer

To participate in this activity, please:

Log in Sign Up

The treatment of patients with breast cancer is increasingly guided by biomarker testing with subsequent therapy targeted to address patient characteristics and needs. To achieve optimal patient outcomes, care is recommended to be provided by an interprofessional, multidisciplinary care team. The principles of interprofessional collaboration and real-world strategies for implementation in the oncology setting are outlined.

Please visit our related course, Adopting the Evolving Management of HR+/HER2-mBC into Practice, by clicking here.

Course Credit:

0.25 AAPA Category I CME Credit
0.25 ACPE Contact Hours
0.25 AMA PRA Category 1 CreditsTM
0.25 ANCC Contact Hours
0.25 CA-BRN Contact Hours

Dates:

Opens: 2026-03-23
Closes: 2027-03-23

Target Audience:

This activity was developed for nurse practitioners, pharmacists, physician associates, and physicians who provide care to patients with HR+/HER2- metastatic breast cancer.

This activity was self-funded by Annenberg Center for Health Sciences.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 hours AAPA Category 1 CME credits. Approval is valid until March 23, 2027. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.25 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Alexa Basilio, PharmD, BCOP (Medical Writer)

Employee: McKesson


Melissa Ketchum, CHCP (Planner)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Christopher Flores, MD

    Family Medicine Physician
    Eisenhower Medical Center
    Rancho Mirage, California

  • Sara A. Hurvitz, MD headshot

    Sara A. Hurvitz, MD

    Professor of Medicine
    Smith Family Endowed Chair in Women’s Health
    Head, Division of Hematology and Oncology | Senior Vice President, Clinical Research Division
    Department of Medicine, UW Medicine | Fred Hutchinson Cancer Center
    Seattle, Washington

  • LaTosha Mollette, DNP

    Family Nurse Practitioner
    Louisiana Family Medicine Clinic
    Jonesboro, Louisiana

  • Hope S. Rugo, MD headshot

    Hope S. Rugo, MD

    Professor of Medicine
    Winterhof Family Distinguished Professor of Breast Oncology
    University of California San Francisco Comprehensive Cancer Center
    San Francisco, California

  • Michael Smith, PharmD

    Clinical Pharmacist in Pain/Palliative Care
    University of Michigan
    Ann Arbor, Michigan

Learning Objectives

  • Describe the evolution in the treatment landscape for patients with HR+/HER2- metastatic breast cancer
  • Identify strategies to improve interprofessional care of patients with HR+/HER2- metastatic breast cancer

Faculty Disclosures

Christopher Flores, MD

No relationships to disclose.

Sara A. Hurvitz, MD

Advisory Board: BriaCell, Gilead

Consultant: BeiGene, BridgeBio, Luminate

Data Safety Monitoring Board: Atossa, InClin, Inc.                   

Research Support: Arvinas, AstraZeneca, Dantari, Daiichi Sankyo, Lilly, G1-Therapeutics, Genentech, Gilead, Greenwich LifeScience, Immunomedics, Jazz, Menarini, Novartis, Orum, Roche, Orinove, Pfizer, PUMA, Radius, Sanofi, Seattle Genetics, Seagen, Stemline Therapeutics, Zymeworks

Steering Committee: Boehringer Ingelheim, BriaCell, Orum


LaTosha Mollette, DNP

No relationships to disclose.

Hope S. Rugo, MD

Consultant: Chugai, Mylan, Napo, Puma, Sanofi

Research Support: Ambryx, AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Lilly, Merck, Novartis, OBI Pharma, Pfizer, Roche, Stemline Therapeutics


Michael Smith, PharmD

No relationships to disclose.